<DOC>
	<DOCNO>NCT01711632</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , treatment vemurafenib ( also know Zelboraf™ ) patient leukemia . Specifically , researcher want know well vemurafenib eliminates leukemia blood .</brief_summary>
	<brief_title>BRAF Inhibitor , Vemurafenib , Patients With Relapsed Refractory Hairy Cell Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<criteria>≥ 18 year age Histologically confirm classical HCL one following : Intolerance purine analog consider poor candidate purine analogbased therapy Failure achieve response ( CR PR ) initial purine analogbased therapy Relapse ≤ 2 year purine analogbased therapy ≥ 2 relapse Histologic confirmation diagnosis perform MSKCC participate site . Patients meet standard treatment initiation criterion , define ANC ≤1.0 , Hgb ≤ 10.0 PLT ≤100K ECOG performance status 02 Acceptable prestudy organ function screen define : Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5x ULN , serum creatinine ≤ 1.5x ULN Electrocardiogram ( ECG ) without evidence clinically significant ventricular arrhythmia ischemia determine investigator ratecorrected QT interval ( QTc , Bazett 's formula ) &lt; 480 msec . For woman childbearing potential , agreement use two acceptable method contraception , include one barrier method , study 6 month discontinuation vemurafenib For men female partner childbearing potential , agreement use latex condom advise female partner use additional method contraception study 6 month discontinuation vemurafenib Negative serum pregnancy test within 7 day commencement treatment premenopausal woman . Agreement donate blood blood product study least 6 month discontinuation vemurafenib ; male partner , agreement donate sperm study least 6 month discontinuation vemurafenib Ability understand willingness sign write informed consent document . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Pregnant breastfeeding Have chemotherapy ( include purine analog , rituximab , investigational agent ) within six week prior enter study Major surgery within 4 week prior enter study Invasive malignancy within past 2 year prior first study drug administration , except adequately treat ( curative intent ) basal squamous cell carcinoma , melanoma , situ carcinoma cervix , situ ductal adenocarcinoma breast , situ prostate cancer , limited stage bladder cancer cancer patient diseasefree least 2 year Refractory nausea vomiting , malabsorption , external biliary shunt , history type gastrointestinal surgery would preclude adequate absorption study drug Prior treatment MEK BRAF inhibitor Active HIV , hepatitis B hepatitis C Patients HCL variant ( define absence expression CD25 absence BRAF V600E mutation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>VEMURAFENIB</keyword>
	<keyword>BRAF Inhibitor</keyword>
	<keyword>12-200</keyword>
	<keyword>Zelboraf™</keyword>
</DOC>